ATLANTA--(BUSINESS WIRE)--Results from a Phase III trial in patients undergoing total hip replacement surgery presented today showed that administration of the oral, once-daily, investigational anticoagulant, rivaroxaban, was statistically superior to once-daily subcutaneous administration of enoxaparin, the current standard of care in preventing venous thromboembolism (VTE) in patients following hip replacement surgery. Rivaroxaban is being jointly developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare AG.
